MedTrace Logo

Oral Lactobacillus Crispatus LCr86 Reduces Nugent Score and Improves Vaginal Microecology in Women With Intermediate Vaginal Microbiota

NCT06830122 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-26

No results posted yet for this study

Summary

Lactobacillus crispatus LCr86 was selected as a test preparation to evaluate its effect on the Nugent score, vaginal pH, vaginal microbiota composition, serum inflammatory cytokines, and functional prediction analyse.

Conditions

  • Patients With Bacterial Vaginosis

Interventions

DIETARY_SUPPLEMENT

Probiotic

The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 2, week 4, week 8).

DIETARY_SUPPLEMENT

Placebo

The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 2, week 4, week 8).

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-01-10
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06830122 on ClinicalTrials.gov